Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer

Alexander L. Chin, Kiran A. Kumar, Haiwei H. Guo, Peter G. Maxim, Heather Wakelee, Joel W. Neal, Maximillian Diehn, Billy W. Loo, Michael F. Gensheimer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We conducted a retrospective study of oligometastatic non–small-cell lung cancer patients who underwent pretreatment fluorodeoxyglucose positron emission tomography imaging and received high-dose radiotherapy to all sites of disease. A greater metabolic tumor burden was associated with shorter overall survival not explained by the number of lesions or maximum standardized uptake value. Biomarkers might help to better select oligometastatic patients for locally ablative therapy. Background: Emerging data support aggressive local treatment of oligometastatic non–small-cell lung cancer (NSCLC) patients. We sought to determine whether the metabolic burden of disease found by fluorodeoxyglucose positron emission tomography at the time of high-dose radiotherapy (RT) for oligometastatic NSCLC can serve as a prognostic biomarker. Materials and Methods: We conducted a retrospective cohort study of 67 RT treatment courses in 55 patients with oligometastatic NSCLC who had undergone high-dose RT to all sites of active disease at our institution. The metabolic tumor volume, total lesion glycolysis (TLG), and maximum standardized uptake value of all lesions were measured on the pretreatment fluorodeoxyglucose positron emission tomography scans. Cox regression analysis was used to assess the influence of imaging and clinical factors on overall survival (OS). Results: On univariate analysis, a greater metabolic tumor volume and TLG were predictive of shorter OS (hazard ratio of death, 2.42 and 2.14, respectively; P =.009 and P =.004, respectively). The effects remained significant on multivariate analysis. Neither the maximum standardized uptake value nor the number of lesions was significantly associated with OS. Patients within the highest quartile of TLG values (> 86.8 units) had a shorter median OS than those within the lower 3 quartiles (12.4 vs. 30.1 months; log-rank P =.014). Conclusion: The metabolic tumor burden was prognostic of OS and might help to better select oligometastatic NSCLC patients for locally ablative therapy.

Original languageEnglish (US)
Pages (from-to)e581-e588
JournalClinical Lung Cancer
Volume19
Issue number5
DOIs
StatePublished - Sep 2018
Externally publishedYes

Fingerprint

Image-Guided Radiotherapy
Non-Small Cell Lung Carcinoma
Tumor Burden
Survival
Glycolysis
Radiotherapy
Positron-Emission Tomography
Retrospective Studies
Biomarkers
Metabolic Diseases
Therapeutics
Catalytic Domain
Cohort Studies
Multivariate Analysis
Regression Analysis

Keywords

  • Ablative radiotherapy
  • Biomarker
  • Metabolic tumor volume
  • Survival
  • Total lesion glycolysis

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer. / Chin, Alexander L.; Kumar, Kiran A.; Guo, Haiwei H.; Maxim, Peter G.; Wakelee, Heather; Neal, Joel W.; Diehn, Maximillian; Loo, Billy W.; Gensheimer, Michael F.

In: Clinical Lung Cancer, Vol. 19, No. 5, 09.2018, p. e581-e588.

Research output: Contribution to journalArticle

Chin, Alexander L. ; Kumar, Kiran A. ; Guo, Haiwei H. ; Maxim, Peter G. ; Wakelee, Heather ; Neal, Joel W. ; Diehn, Maximillian ; Loo, Billy W. ; Gensheimer, Michael F. / Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer. In: Clinical Lung Cancer. 2018 ; Vol. 19, No. 5. pp. e581-e588.
@article{07b9346b6b904064a8b0ccd83249e9d8,
title = "Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer",
abstract = "We conducted a retrospective study of oligometastatic non–small-cell lung cancer patients who underwent pretreatment fluorodeoxyglucose positron emission tomography imaging and received high-dose radiotherapy to all sites of disease. A greater metabolic tumor burden was associated with shorter overall survival not explained by the number of lesions or maximum standardized uptake value. Biomarkers might help to better select oligometastatic patients for locally ablative therapy. Background: Emerging data support aggressive local treatment of oligometastatic non–small-cell lung cancer (NSCLC) patients. We sought to determine whether the metabolic burden of disease found by fluorodeoxyglucose positron emission tomography at the time of high-dose radiotherapy (RT) for oligometastatic NSCLC can serve as a prognostic biomarker. Materials and Methods: We conducted a retrospective cohort study of 67 RT treatment courses in 55 patients with oligometastatic NSCLC who had undergone high-dose RT to all sites of active disease at our institution. The metabolic tumor volume, total lesion glycolysis (TLG), and maximum standardized uptake value of all lesions were measured on the pretreatment fluorodeoxyglucose positron emission tomography scans. Cox regression analysis was used to assess the influence of imaging and clinical factors on overall survival (OS). Results: On univariate analysis, a greater metabolic tumor volume and TLG were predictive of shorter OS (hazard ratio of death, 2.42 and 2.14, respectively; P =.009 and P =.004, respectively). The effects remained significant on multivariate analysis. Neither the maximum standardized uptake value nor the number of lesions was significantly associated with OS. Patients within the highest quartile of TLG values (> 86.8 units) had a shorter median OS than those within the lower 3 quartiles (12.4 vs. 30.1 months; log-rank P =.014). Conclusion: The metabolic tumor burden was prognostic of OS and might help to better select oligometastatic NSCLC patients for locally ablative therapy.",
keywords = "Ablative radiotherapy, Biomarker, Metabolic tumor volume, Survival, Total lesion glycolysis",
author = "Chin, {Alexander L.} and Kumar, {Kiran A.} and Guo, {Haiwei H.} and Maxim, {Peter G.} and Heather Wakelee and Neal, {Joel W.} and Maximillian Diehn and Loo, {Billy W.} and Gensheimer, {Michael F.}",
year = "2018",
month = "9",
doi = "10.1016/j.cllc.2018.04.003",
language = "English (US)",
volume = "19",
pages = "e581--e588",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer

AU - Chin, Alexander L.

AU - Kumar, Kiran A.

AU - Guo, Haiwei H.

AU - Maxim, Peter G.

AU - Wakelee, Heather

AU - Neal, Joel W.

AU - Diehn, Maximillian

AU - Loo, Billy W.

AU - Gensheimer, Michael F.

PY - 2018/9

Y1 - 2018/9

N2 - We conducted a retrospective study of oligometastatic non–small-cell lung cancer patients who underwent pretreatment fluorodeoxyglucose positron emission tomography imaging and received high-dose radiotherapy to all sites of disease. A greater metabolic tumor burden was associated with shorter overall survival not explained by the number of lesions or maximum standardized uptake value. Biomarkers might help to better select oligometastatic patients for locally ablative therapy. Background: Emerging data support aggressive local treatment of oligometastatic non–small-cell lung cancer (NSCLC) patients. We sought to determine whether the metabolic burden of disease found by fluorodeoxyglucose positron emission tomography at the time of high-dose radiotherapy (RT) for oligometastatic NSCLC can serve as a prognostic biomarker. Materials and Methods: We conducted a retrospective cohort study of 67 RT treatment courses in 55 patients with oligometastatic NSCLC who had undergone high-dose RT to all sites of active disease at our institution. The metabolic tumor volume, total lesion glycolysis (TLG), and maximum standardized uptake value of all lesions were measured on the pretreatment fluorodeoxyglucose positron emission tomography scans. Cox regression analysis was used to assess the influence of imaging and clinical factors on overall survival (OS). Results: On univariate analysis, a greater metabolic tumor volume and TLG were predictive of shorter OS (hazard ratio of death, 2.42 and 2.14, respectively; P =.009 and P =.004, respectively). The effects remained significant on multivariate analysis. Neither the maximum standardized uptake value nor the number of lesions was significantly associated with OS. Patients within the highest quartile of TLG values (> 86.8 units) had a shorter median OS than those within the lower 3 quartiles (12.4 vs. 30.1 months; log-rank P =.014). Conclusion: The metabolic tumor burden was prognostic of OS and might help to better select oligometastatic NSCLC patients for locally ablative therapy.

AB - We conducted a retrospective study of oligometastatic non–small-cell lung cancer patients who underwent pretreatment fluorodeoxyglucose positron emission tomography imaging and received high-dose radiotherapy to all sites of disease. A greater metabolic tumor burden was associated with shorter overall survival not explained by the number of lesions or maximum standardized uptake value. Biomarkers might help to better select oligometastatic patients for locally ablative therapy. Background: Emerging data support aggressive local treatment of oligometastatic non–small-cell lung cancer (NSCLC) patients. We sought to determine whether the metabolic burden of disease found by fluorodeoxyglucose positron emission tomography at the time of high-dose radiotherapy (RT) for oligometastatic NSCLC can serve as a prognostic biomarker. Materials and Methods: We conducted a retrospective cohort study of 67 RT treatment courses in 55 patients with oligometastatic NSCLC who had undergone high-dose RT to all sites of active disease at our institution. The metabolic tumor volume, total lesion glycolysis (TLG), and maximum standardized uptake value of all lesions were measured on the pretreatment fluorodeoxyglucose positron emission tomography scans. Cox regression analysis was used to assess the influence of imaging and clinical factors on overall survival (OS). Results: On univariate analysis, a greater metabolic tumor volume and TLG were predictive of shorter OS (hazard ratio of death, 2.42 and 2.14, respectively; P =.009 and P =.004, respectively). The effects remained significant on multivariate analysis. Neither the maximum standardized uptake value nor the number of lesions was significantly associated with OS. Patients within the highest quartile of TLG values (> 86.8 units) had a shorter median OS than those within the lower 3 quartiles (12.4 vs. 30.1 months; log-rank P =.014). Conclusion: The metabolic tumor burden was prognostic of OS and might help to better select oligometastatic NSCLC patients for locally ablative therapy.

KW - Ablative radiotherapy

KW - Biomarker

KW - Metabolic tumor volume

KW - Survival

KW - Total lesion glycolysis

UR - http://www.scopus.com/inward/record.url?scp=85047222755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047222755&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.04.003

DO - 10.1016/j.cllc.2018.04.003

M3 - Article

C2 - 29759331

AN - SCOPUS:85047222755

VL - 19

SP - e581-e588

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 5

ER -